These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 20203507

  • 1. Aminosalicylates and other anti-inflammatory compounds for irritable bowel syndrome.
    Barbara G, Stanghellini V, Cremon C, De Giorgio R, Fronzoni L, Serra M, Corinaldesi R.
    Dig Dis; 2009; 27 Suppl 1():115-21. PubMed ID: 20203507
    [Abstract] [Full Text] [Related]

  • 2. Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome.
    Barbara G, Zecchi L, Barbaro R, Cremon C, Bellacosa L, Marcellini M, De Giorgio R, Corinaldesi R, Stanghellini V.
    J Clin Gastroenterol; 2012 Oct; 46 Suppl():S52-5. PubMed ID: 22955358
    [Abstract] [Full Text] [Related]

  • 3. Probiotics and irritable bowel syndrome: rationale and clinical evidence for their use.
    Barbara G, Stanghellini V, Cremon C, De Giorgio R, Gargano L, Cogliandro R, Pallotti F, Corinaldesi R.
    J Clin Gastroenterol; 2008 Sep; 42 Suppl 3 Pt 2():S214-7. PubMed ID: 18685517
    [Abstract] [Full Text] [Related]

  • 4. Mesalazine (5-aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea-predominant irritable bowel syndrome.
    Andrews CN, Griffiths TA, Kaufman J, Vergnolle N, Surette MG, Rioux KP.
    Aliment Pharmacol Ther; 2011 Aug; 34(3):374-83. PubMed ID: 21671966
    [Abstract] [Full Text] [Related]

  • 5. Mucosal barrier defects in irritable bowel syndrome. Who left the door open?
    Barbara G.
    Am J Gastroenterol; 2006 Jun; 101(6):1295-8. PubMed ID: 16771952
    [Abstract] [Full Text] [Related]

  • 6. Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms.
    Cremon C, Gargano L, Morselli-Labate AM, Santini D, Cogliandro RF, De Giorgio R, Stanghellini V, Corinaldesi R, Barbara G.
    Am J Gastroenterol; 2009 Feb; 104(2):392-400. PubMed ID: 19174797
    [Abstract] [Full Text] [Related]

  • 7. Will corticosteroids and other anti-inflammatory agents be effective for diarrhea-predominant irritable bowel syndrome?
    Crentsil V.
    Med Hypotheses; 2005 Feb; 65(1):97-102. PubMed ID: 15893125
    [Abstract] [Full Text] [Related]

  • 8. The putative role of the intestinal microbiota in the irritable bowel syndrome.
    Collins SM, Denou E, Verdu EF, Bercik P.
    Dig Liver Dis; 2009 Dec; 41(12):850-3. PubMed ID: 19740713
    [Abstract] [Full Text] [Related]

  • 9. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome.
    Barbara G, Wang B, Stanghellini V, de Giorgio R, Cremon C, Di Nardo G, Trevisani M, Campi B, Geppetti P, Tonini M, Bunnett NW, Grundy D, Corinaldesi R.
    Gastroenterology; 2007 Jan; 132(1):26-37. PubMed ID: 17241857
    [Abstract] [Full Text] [Related]

  • 10. Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome.
    Cremon C, Carini G, Wang B, Vasina V, Cogliandro RF, De Giorgio R, Stanghellini V, Grundy D, Tonini M, De Ponti F, Corinaldesi R, Barbara G.
    Am J Gastroenterol; 2011 Jul; 106(7):1290-8. PubMed ID: 21427712
    [Abstract] [Full Text] [Related]

  • 11. Chronological assessment of mast cell-mediated gut dysfunction and mucosal inflammation in a rat model of chronic psychosocial stress.
    Vicario M, Guilarte M, Alonso C, Yang P, Martínez C, Ramos L, Lobo B, González A, Guilà M, Pigrau M, Saperas E, Azpiroz F, Santos J.
    Brain Behav Immun; 2010 Oct; 24(7):1166-75. PubMed ID: 20600818
    [Abstract] [Full Text] [Related]

  • 12. Mucosal immune cell numbers and visceral sensitivity in patients with irritable bowel syndrome: is there any relationship?
    Braak B, Klooker TK, Wouters MM, Welting O, van der Loos CM, Stanisor OI, van Diest S, van den Wijngaard RM, Boeckxstaens GE.
    Am J Gastroenterol; 2012 May; 107(5):715-26. PubMed ID: 22488080
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Review article: Associations between immune activation, intestinal permeability and the irritable bowel syndrome.
    Matricon J, Meleine M, Gelot A, Piche T, Dapoigny M, Muller E, Ardid D.
    Aliment Pharmacol Ther; 2012 Dec; 36(11-12):1009-31. PubMed ID: 23066886
    [Abstract] [Full Text] [Related]

  • 16. Treatment of diarrhea-predominant irritable bowel syndrome with mesalazine and/or Saccharomyces boulardii.
    Bafutto M, Almeida JR, Leite NV, Costa MB, Oliveira EC, Resende-Filho J.
    Arq Gastroenterol; 2013 Dec; 50(4):304-9. PubMed ID: 24474234
    [Abstract] [Full Text] [Related]

  • 17. Mast cells and nerves tickle in the tummy: implications for inflammatory bowel disease and irritable bowel syndrome.
    Rijnierse A, Nijkamp FP, Kraneveld AD.
    Pharmacol Ther; 2007 Nov; 116(2):207-35. PubMed ID: 17719089
    [Abstract] [Full Text] [Related]

  • 18. Overlap between irritable bowel syndrome and inflammatory bowel disease.
    Spiller RC.
    Dig Dis; 2009 Nov; 27 Suppl 1():48-54. PubMed ID: 20203497
    [Abstract] [Full Text] [Related]

  • 19. Editorial: Can gluten contribute to irritable bowel syndrome?
    Verdu EF.
    Am J Gastroenterol; 2011 Mar; 106(3):516-8. PubMed ID: 21378766
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.